INTRODUCTION: Patient adherence to smoking cessation medications can impact their effectiveness. It is important to understand the extent to which prescribed medications are actually taken by smokers, how this influences smoking cessation outcomes, and what factors may influence adherence. METHODS:Smokers recruited from a large health plan were randomized to receive different modes of cessation counseling in combination with varenicline (Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. 2010.Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490). One thousand one hundred and sixty-one participants were mailed a 28-day varenicline supply when they set a quit date and were able to request up to two refills from the health plan pharmacy at no cost. Pharmacy fill records were obtained and telephone surveys completed at baseline, 21 days, 12 weeks, and 6 months post target quit date. RESULTS: Good adherence to varenicline (≥80% of days taken) was associated with a twofold increase in 6-month quit rates compared with poor adherence (52% vs. 25%). Smokers were more likely than nonsmokers to stop varenicline early. Purposeful nonadherence was associated with smoking at 12 weeks and was predicted in multivariate analyses by age, gender, adherence self-efficacy, and initial medication side effect severity. CONCLUSIONS: Innovative methods for increasing adherence to smoking cessation medications are needed, particularly early in the quit process. Simple metrics of adherence such as number of days cessation medication is taken can and should be routinely incorporated in effectiveness trials and reported to advance future attempts to understand and reduce nonadherence.
RCT Entities:
INTRODUCTION:Patient adherence to smoking cessation medications can impact their effectiveness. It is important to understand the extent to which prescribed medications are actually taken by smokers, how this influences smoking cessation outcomes, and what factors may influence adherence. METHODS: Smokers recruited from a large health plan were randomized to receive different modes of cessation counseling in combination with varenicline (Swan, G. E., McClure, J. B., Jack, L. M., Zbikowski, S. M., Javitz, H. S., Catz, S. L., et al. 2010.Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38, 482-490). One thousand one hundred and sixty-one participants were mailed a 28-day varenicline supply when they set a quit date and were able to request up to two refills from the health plan pharmacy at no cost. Pharmacy fill records were obtained and telephone surveys completed at baseline, 21 days, 12 weeks, and 6 months post target quit date. RESULTS: Good adherence to varenicline (≥80% of days taken) was associated with a twofold increase in 6-month quit rates compared with poor adherence (52% vs. 25%). Smokers were more likely than nonsmokers to stop varenicline early. Purposeful nonadherence was associated with smoking at 12 weeks and was predicted in multivariate analyses by age, gender, adherence self-efficacy, and initial medication side effect severity. CONCLUSIONS: Innovative methods for increasing adherence to smoking cessation medications are needed, particularly early in the quit process. Simple metrics of adherence such as number of days cessation medication is taken can and should be routinely incorporated in effectiveness trials and reported to advance future attempts to understand and reduce nonadherence.
Authors: Joel D Killen; Thomas N Robinson; Seth Ammerman; Chris Hayward; Jayna Rogers; Christi Stone; Deanne Samuels; Sara K Levin; Sarah Green; Alan F Schatzberg Journal: J Consult Clin Psychol Date: 2004-08
Authors: A J Garvey; T Kinnunen; B L Nordstrom; C H Utman; K Doherty; B Rosner; P S Vokonas Journal: Nicotine Tob Res Date: 2000-02 Impact factor: 4.244
Authors: Tanya R Schlam; Timothy B Baker; Stevens S Smith; Daniel M Bolt; Danielle E McCarthy; Jessica W Cook; Todd Hayes-Birchler; Michael C Fiore; Megan E Piper Journal: Nicotine Tob Res Date: 2020-10-29 Impact factor: 4.244
Authors: Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen Journal: Nicotine Tob Res Date: 2012-02-24 Impact factor: 4.244
Authors: Allison J Carroll; Anna K Veluz-Wilkins; Sonja Blazekovic; Ravi Kalhan; Frank T Leone; E Paul Wileyto; Robert A Schnoll; Brian Hitsman Journal: Psychooncology Date: 2017-08-04 Impact factor: 3.894
Authors: Grace Crawford; Jessica Weisbrot; Joseph Bastian; Alex Flitter; Nancy C Jao; Allison Carroll; Ravi Kalhan; Frank Leone; Brian Hitsman; Robert Schnoll Journal: Nicotine Tob Res Date: 2019-07-17 Impact factor: 4.244
Authors: Sandra J Japuntich; Christina M Luberto; Joanna M Streck; Nancy A Rigotti; Jennifer Temel; Michael Lanuti; Carolyn Dresler; Jennifer P Zallen; Diane Davies; Elyse R Park Journal: J Health Psychol Date: 2015-06-04
Authors: G R Kruse; E Park; J E Haberer; L Abroms; N N Shahid; S E Howard; Y Chang; J S Haas; N A Rigotti Journal: Contemp Clin Trials Date: 2019-03-25 Impact factor: 2.226
Authors: Stevens S Smith; Paula A Keller; Kate H Kobinsky; Timothy B Baker; David L Fraser; Terry Bush; Brooke Magnusson; Susan M Zbikowski; Timothy A McAfee; Michael C Fiore Journal: Nicotine Tob Res Date: 2012-09-19 Impact factor: 4.244
Authors: Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll Journal: Addict Behav Date: 2017-07-12 Impact factor: 3.913